NCT04041050 2025-02-14
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
AbbVie
Phase 1 Active not recruiting
AbbVie
OHSU Knight Cancer Institute